

**PRESS RELEASE FROM
NEUROPSYCHOPHARMACOLOGY
(<http://www.nature.com/npp>)**

**This press release is copyrighted to the journal *Neuropsychopharmacology*.
Its use is granted only for journalists and news media receiving it directly from the Nature
Publishing Group.**

*** PLEASE DO NOT REDISTRIBUTE THIS DOCUMENT ***

EMBARGO:

**1430 London time (GMT) / 0930 US Eastern time Wednesday 31 March
2330pm Japanese time Wednesday 31 March / 0130 Australian Eastern time Thursday 1
April**

**Wire services' stories must always carry the embargo time at the head of each item, and
may not be sent out more than 24 hours before that time.**

**Solely for the purpose of soliciting informed comment on this paper, you may show it to
independent specialists - but you must ensure in advance that they understand and accept
the embargo conditions.**

A PDF of the paper mentioned on this release can be found in the Academic journals section of
<http://press.nature.com>. Press contacts for the journals are listed at the end of this release.

**Warning: This document, and the Academic Journal paper to which it refers, may contain
information that is price sensitive (as legally defined, for example, in the UK Criminal
Justice Act 1993 Part V) with respect to publicly quoted companies. Anyone dealing in
securities using information contained in this document or in advanced copies of *Nature's*
content may be guilty of insider trading under the US Securities Exchange Act of 1934.**

PICTURES: While we are happy for images from *Neuropsychopharmacology* to be reproduced
for the purposes of contemporaneous news reporting, you must also seek permission from the
copyright holder (if named) or author of the research paper in question (if not).

HYPE: We take great care not to hype the papers mentioned on our press releases, but are
sometimes accused of doing so. If you ever consider that a story has been hyped, please do not
hesitate to contact us at press@nature.com, citing the specific example.

PLEASE CITE *NEUROPSYCHOPHARMACOLOGY* AND THE
NEUROPSYCHOPHARMACOLOGY WEBSITE AS THE SOURCE OF THE FOLLOWING ITEM.
IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO www.nature.com/npp/

[How lithium treats bipolar disorder](#)

DOI: 10.1038/npp.2010.41

Sustained increases in gray matter volume may be the key to explaining how lithium helps to treat bipolar disorder, according to a study published online this week in *Neuropsychopharmacology*. As lithium is thought to lower the risk of developing Alzheimer's disease and protect against dementia development in bipolar disorder patients, this research could potentially lead to future research into the effects of lithium on other neurodegenerative diseases.

The international collaborative team of In Kyoon Lyoo, Stephen Dager, Perry Renshaw and colleagues took 22 bipolar disorder patients who had never taken mood-stabilizing or

antipsychotic medications and treated them with either lithium or valproic acid (VPA). The results of a longitudinal brain imaging study showed noticeable increases in gray matter volume in the lithium-treated patients, but not in the VPA-treated ones. These increases were sustained over 16 weeks of treatment and were associated with an improvement in symptoms. This suggests that lithium causes regeneration of gray matter that normalizes deficits in the brains of bipolar disorder patients.

Interestingly, while VPA-treated patients experienced a similar improvement in symptoms, they did not have an increase in gray matter volume. This suggests a different but also effective mechanism of action for this drug – a theory which will require further study.

Author contacts:

In Kyoon Lyoo (Departments of Psychiatry and Neuroscience, Seoul National University, South Korea)

Tel: +82 2 2072-2302; E-mail: inkyloo@snu.ac.kr

Stephen Dager (Departments of Radiology and Bioengineering, University of Washington, Seattle, WA, USA)

Tel: +1 206-616-1558; E-mail: srd@u.washington.edu

Perry Renshaw (Department of Psychiatry, University of Utah, Salt Lake City, UT, USA)

Tel: +1 801-587-1216; E-mail: perry.renshaw@hsc.utah.edu

Editorial contact:

Diane Drexler (Neuropsychopharmacology, Nashville, TN, USA)

Tel: +1 615 324 2371; E-mail: journal@acnp.org

Press contacts:

For media inquiries relating to embargo policy for the Journal Neuropsychopharmacology:

Neda Afsarmanesh (Nature New York)

Tel: +1 212 726 9231; E-mail: n.afsarmanesh@us.nature.com

Ruth Francis (Nature London)

Tel: +44 20 7843 4562; E-mail: r.francis@nature.com

For media inquiries relating to the American College of Neuropsychopharmacology:

Tel: +1 615 324 2360; E-mail: acnp@acnp.org

About Nature Publishing Group (NPG)

Nature Publishing Group (NPG) is a publisher of high impact scientific and medical information in print and online. NPG publishes journals, online databases and services across the life, physical, chemical and applied sciences and clinical medicine.

Focusing on the needs of scientists, *Nature* (founded in 1869) is the leading weekly, international scientific journal. In addition, for this audience, NPG publishes a range of *Nature* research journals and *Nature Reviews* journals, plus a range of prestigious academic journals including society-owned publications. Online, nature.com provides over 5 million visitors per month with access to NPG publications and online databases and services, including *Nature News* and *NatureJobs* plus access to *Nature Network* and Nature Education's Scitable.com.

Scientific American is at the heart of NPG's newly-formed consumer media division, meeting the needs of the general public. Founded in 1845, *Scientific American* is the oldest continuously published magazine in the US and the leading authoritative publication for science in the general media. Together with scientificamerican.com and 15 local language editions around the world it

reaches over 3 million consumers and scientists. Other titles include *Scientific American Mind* and *Spektrum der Wissenschaft* in Germany.

Throughout all its businesses NPG is dedicated to serving the scientific and medical communities and the wider scientifically interested general public. Part of Macmillan Publishers Limited, NPG is a global company with principal offices in London, New York and Tokyo, and offices in cities worldwide including Boston, Buenos Aires, Delhi, Hong Kong, Madrid, Barcelona, Munich, Heidelberg, Basingstoke, Melbourne, Paris, San Francisco, Seoul and Washington DC. For more information, please go to www.nature.com.